Annex A - Discussion paper on novel formulations of supplement compounds designed to increase oral bioavailability

Abbreviations

In this guide

In this guide

- 1. <u>Contents Annex A</u>
- 2. Background Annex A
- 3. Novel formulations of supplement compounds Annex A
- 4. Lipid-based delivery systems Annex A
- 5. Other systems to increase bioavailability Annex A
- 6. Uncertainties surrounding novel supplement formulations Annex A
- 7. Market data and projected trends Annex A
- 8. <u>Case studies of supplement formulations with increased bioavailability -</u> <u>Annex A</u>
- 9. Case study 1: Liposomal vitamin C Annex A
- 10. Case study 2: Curcuminoids Annex A
- 11. Case study 3: Cannabidiol Annex A
- 12. Toxicology studies with novel supplement formulations Annex A
- 13. Summary and discussion Annex A
- 14. Questions for the Committee Annex A
- 15. Abbreviations Annex A
- 16. Glossary Annex A
- 17. <u>References Annex A</u>
- 18. <u>Appendix A: Literature search for specific toxicology studies with novel</u> <u>supplement formulations</u>
- ASA Advertising Standards Authority
- AUC0-n Integrated area under the time-concentration curve following administration of a compound from 0 to n hours.

BCM-95	Curcumin formulation composed of 95% standardised curcuminoids and turmeric essential oils.
BDMC	Bisdemethoxycurcumin
ВМІ	Body mass index
CBD	Cannabidiol
Cmax	Highest plasma concentration achieved following administration of a compound.
сот	The Committee on Toxicity of Chemicals in Food, Consumer Products, and the Environment
DAGs	Diacylglycerols
DMC	Demethoxycurcumin
FFA	Free fatty acids
GIT	Gastrointestinal tract
GRAS	Generally recognised as safe.
HBGV	Health-based guidance value
LCFA	Long chain fatty acids
MAGs	Monoacylglycerols
МСТ	Medium chain triglycerides

MTHF	Methyltetrahydrofolate
NAD+	Nicotinamide adenine dinucleotide
NIH	National Institutes of Health
NLC	Nanostructured lipid carriers
NMN	Nicotinamide mononucleotide
PDI -	Polydispersity index
SE(M/N)DDS	Self-emulsifying (micro/nano) drug delivery system
SLCP	Solid lipid curcumin particles
SLN	Solid lipid nanoparticles
тнс	Tetrahydrocurcumin (c.f. the cannabinoid tetrahydrocannabinol 'THC', is not discussed in this paper)
Tmax	Timepoint following administration of a compound at which highest plasma concentration is achieved.